Overview

A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

The primary objectives of this 2-part drug interaction study are as follows: - To evaluate the effect of gemfibrozil on the pharmacokinetics (i.e., amount in the blood) of selexipag and its metabolite ACT-333679 (Part I). - To evaluate the effect of rifampicin on the pharmacokinetics of selexipag and its metabolite ACT-333679 (Part II).

Phase:

Phase 1

Details

Lead Sponsor:

Actelion

Treatments:

Gemfibrozil
Rifampin
Selexipag